[43] Other menin inhibitors such as Ziftomenib [25] and Bleximenib [44] are being studied in addition to the possible combination therapies with venetoclax, hypomethylating agents, PARP inhibitors, all-trans-retinoic acid (ATRA), and other common treatment options in AML [45]. The gene discussed is MEN1; the disease is acute myeloid leukemia.